Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

… the discovery and development of novel antibody-based cancer immunotherapies. Adagene … ’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged … United States, China, Australia, Japan, Singapore, and the European Union. Safe …